Back to top
more

QuidelOrtho (QDEL)

(Delayed Data from NSDQ)

$44.19 USD

44.19
648,432

-0.01 (-0.02%)

Updated May 31, 2024 04:00 PM ET

After-Market: $44.18 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for QDEL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

QuidelOrtho Corporation [QDEL]

Reports for Purchase

Showing records 121 - 140 ( 185 total )

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 121

10/17/2013

Company Report

Pages: 10

3Q13 Preview - Expecting In-Line Results - Early Flu Sales Likely Ok

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 122

07/31/2013

Company Report

Pages: 10

Mellow 2Q13, As Expected - Slight Top-line Miss Due to Strep A - Minimal Sofia Color - AmpliVue Tone More Encouraging - Reaffirm UP - PT to $18

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 123

07/22/2013

Company Report

Pages: 7

2Q13 Preview - Revenue & EPS Matter Little - Sofia Utilization Potential & Wildcat Progress Remain Key - Maintaining UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 124

04/24/2013

Company Report

Pages: 11

1Q13 Results Fine - Sleepy Call - Flu Sales As Expected

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 125

04/17/2013

Company Report

Pages: 8

1Q13 Preview - Expecting Better Flu Sales - Channel Inventory Murky - Sofia Placements, Utilization & Molecular Story Key - Maintain UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 126

04/09/2013

Company Report

Pages: 8

Fine-Tuning Estimates - Lowering 1Q13 Flu Sales Estimates Following Checks - Maintaining UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 127

03/04/2013

Company Report

Pages: 15

Downgrading to UNDERPERFORM from NEUTRAL on Valuation and Wildcat Hype - New Details Expected at Analyst Day This Week - Competition Fierce

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 50.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 128

02/13/2013

Company Report

Pages: 10

4Q12 Recap - In-line Revs - Stronger EPS - Flu Comments Support Our Above-Consensus 1Q13 View

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 129

02/11/2013

Company Report

Pages: 13

4Q12 Preview - Flu Well Understood - Sofia Ramp & Molecular Progress In Focus

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 50.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 130

02/04/2013

Company Report

Pages: 13

Week 4 Flu Update - Loitering Flu Likely Driving Stronger 1Q13 Orders

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 50.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 131

01/22/2013

Daily Note

Pages: 13

Week 2 Flu Update - Activity Remains High

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 50.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 132

01/14/2013

Daily Note

Pages: 13

Week 1 Flu Update - Positive Cases & Floogle Indicator Jump Again Wk/Wk - Total Activity Surpasses Prior Year - Mortality Rate Up - Maintain NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 50.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 133

12/10/2012

Daily Note

Pages: 12

Week 48 Flu Update - US Activity Continues to Ramp

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 134

12/03/2012

Company Report

Pages: 14

Flu Activity Ramping - On Track to Beat Last Two Seasons in Timing and Intensity - Upping 2013 Estimates

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 50.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 135

10/24/2012

Company Report

Pages: 10

3Q12 Unspectacular - Limited Color on Sofia - Flu Sales Off But Inline w/ Seasonal 3Q Variance - Flu Inventory Low - Pipeline On Track - Maintain N

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 136

10/22/2012

Company Report

Pages: 8

3Q12 Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 137

09/11/2012

Daily Note

Pages: 8

Update Post SF Bay Area NDR with CEO - Sofia Body Language Solid - Wildcat Progress Murky - Expect More At March Investor Day - Maintain NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 138

07/25/2012

Company Report

Pages: 10

2Q12 Recap: Results Essentially In Line

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 139

07/23/2012

Company Report

Pages: 8

2Q12 Preview - Expectations Relatively Low - Financials Unlikely to Matter Much - New Product Story and Preliminary Molecular Traction Key

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QuidelOrtho Corporation

Industry: Medical - Products

Record: 140

04/26/2012

Company Report

Pages: 10

1Q12 Recap - a Tad Soft on Revs and EPS - No Major Red Flags - Pipeline Appears on Track - Still Not Feeling the Risk/Reward - Reaffirm NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party